This clinical trial is focused on studying the effects of a medication called Risankizumab on individuals with Psoriatic Arthritis. Psoriatic Arthritis is a type of arthritis that affects some people who have psoriasis, a condition that features red patches of skin topped with silvery scales. The study involves comparing Risankizumab to a placebo to see how well it works in treating the symptoms of Psoriatic Arthritis. Risankizumab is given as a solution for injection using a pre-filled syringe.

The purpose of the study is to evaluate the effectiveness of Risankizumab in reducing the signs and symptoms of Psoriatic Arthritis in participants who have not responded well to or cannot tolerate at least one previous treatment known as a Disease Modifying Anti-Rheumatic Drug (DMARD). Participants will receive either Risankizumab or a placebo, and the study will monitor their progress over a period of time to assess improvements in their condition.

Throughout the study, participants will receive regular injections and attend scheduled visits to track their health and any changes in their symptoms. The study aims to determine if Risankizumab can provide significant relief from the symptoms of Psoriatic Arthritis compared to the placebo. The trial is designed to ensure that all participants are closely monitored for safety and effectiveness of the treatment.